Literature DB >> 15721449

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer.

Bradley J Monk1, David C Choi, Gordon Pugmire, Robert A Burger.   

Abstract

BACKGROUND: Angiogenesis is pivotal in the development and progression of ovarian cancer and is an ideal candidate for novel treatment approaches. CASE: A case of advanced, recurrent and refractory serous carcinoma is presented that responded to bevacizumab 15 mg/m2 intravenously every 3 weeks after failing eleventh line cytotoxic chemotherapy and radiation. An objective durable response lasting at least 5 months was documented.
CONCLUSION: Bevacizumab has activity in epithelial ovarian carcinoma and larger scale trials are indicated.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15721449     DOI： 10.1016/j.ygyno.2004.12.001

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


  30 in total

Review 1.  Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers.

Authors:  Taher Abu-Hejleh; James J Mezhir; Michael J Goodheart; Thorvardur R Halfdanarson
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

Review 2.  B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look.

Authors:  Jenessa B Smith; Caitlin Stashwick; Daniel J Powell
Journal:  Gynecol Oncol       Date:  2014-03-20       Impact factor: 5.482

Review 3.  Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.

Authors:  Ernest S Han; Mark Wakabayashi; Lucille Leong
Journal:  Curr Treat Options Oncol       Date:  2013-03

4.  Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.

Authors:  Kae Hashimoto; Shan Man; Ping Xu; William Cruz-Munoz; Terence Tang; Rakesh Kumar; Robert S Kerbel
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

5.  Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.

Authors:  Robert A Burger
Journal:  J Gynecol Oncol       Date:  2010-03-31       Impact factor: 4.401

Review 6.  Current status of anti-angiogenic agents in the treatment of ovarian carcinoma.

Authors:  Alfonso Sánchez-Muñoz; Elisabeth Pérez-Ruiz; César Mendiola Fernández; Emilio Alba Conejo; Antonio González-Martín
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

7.  Targeted therapies in epithelial ovarian cancer.

Authors:  Nicanor I Barrena Medel; Jason D Wright; Thomas J Herzog
Journal:  J Oncol       Date:  2010-01-13       Impact factor: 4.375

Review 8.  Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.

Authors:  Filippo Bellati; Chiara Napoletano; Ilary Ruscito; Maria Pastore; Milena Pernice; Morena Antonilli; Marianna Nuti; Pierluigi Benedetti Panici
Journal:  Invest New Drugs       Date:  2009-11-24       Impact factor: 3.850

Review 9.  Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review.

Authors:  Susan E Pories; Gerburg M Wulf
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-06-21

10.  Antivascular therapy for epithelial ovarian cancer.

Authors:  Francois P Duhoux; Jean-Pascal Machiels
Journal:  J Oncol       Date:  2009-12-23       Impact factor: 4.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.